Medications in Trials

MODAG's small molecule aims to inhibit aggregation of alpha-synuclein. MJFF funded pre-clinical work and a portion of a Phase I trial in people with Parkinson's.

Biogen’s antibody aims to prevent aggregated alpha-synuclein from spreading. MJFF is funding tool development and data collection that support study design.

Proclara’s (previously Neurophage) drug candidate aims to prevent alpha-synuclein from clumping together. MJFF funded pre-clinical work.

AFFiRiS’ vaccine aims to stimulate antibodies against alpha-synuclein. MJFF funded pre-clinical work, a portion of the Phase I trial and boost studies.

Prothena/Roche’s antibody aims to prevent aggregated alpha-synuclein from spreading. MJFF is funding tool development and data collection that support study design.

Sanofi Genzyme’s drug reduces production of lipids that build up with GBA mutations. MJFF is funding tool development and data collection that support study design.

Lysosomal Therapeutics’ oral drug may offset dysfunction associated with GBA mutation. MJFF funded the pre-clinical work.

Denali’s LRRK2 inhibitor aims to lower heightened LRRK2 activity. MJFF funded safety studies that supported the trial.

Diabetes medication that has protected brain cells in pre-clinical Parkinson’s models. MJFF funded the Phase II trial led by the University of College London.

Nutritional supplement raises urate (antioxidant) levels. Population studies show inosine may have a protective effect or slow progression of PD. MJFF funded pre-clinical work and the Phase II trial and is supporting biomarker collection in the Phase III trial led by the Parkinson Study Group.

High blood pressure drug may help protect brain cells. MJFF funded the pre-clinical work and the Phase II trial and is supporting biomarker collection in the Phase III trial led by the Parkinson Study Group.

This treatment for a cancer of the white blood cells (chronic myelogenous leukemia) may address dysfunction seen in PD. MJFF is funding a Phase II trial led by the Parkinson Study Group.

MedGenesis’ trophic factor may protect dopamine cells. MJFF funded the pre-clinical work.

Herantis’ trophic factor may protect dopamine cells. MJFF funded the pre-clinical work.

Layers of levodopa/carbidopa release slowly from the stomach for better absorption. MJFF funded the pre-clinical work by Intec Pharma.

Neuroderm’s levodopa/carbidopa pump or pump-patch could maintain steady levels of levodopa. MJFF funded a portion of Phase I and Phase II trials.

Prexton Therapeutics’ oral drug (foliglurax) works on the glutamate and other brain chemical systems to reduce motor symptoms and dyskinesia. MJFF funded the pre-clinical work.

Sunovion’s (previously Cynapsus) thin film of the drug apomorphine placed under the tongue could rescue patients from "off" episodes. MJFF funded Phase I and Phase II trials.

Acorda’s (previously Civitas) inhaled levodopa can quickly ease symptoms. MJFF funded Phase I and Phase II trials.

Voyager’s approach aims to replace the enzyme AADC in brain cells to improve levodopa conversion to dopamine for better control of motor symptoms and less “off” time in advanced Parkinson’s. MJFF funded a Phase I trial.

Addex Pharma’s oral drug (dipraglurant) blocks the effects of the brain chemical glutamate, which may decrease dyskinesia. MJFF funded the pre-clinical work and a Phase II trial. 

Amarantus’ drug blocks serotonin receptors. MJFF funded a Phase I trial.

Drug acts on brain chemical acetylcholine and has been shown to reduce falls in PD patients. MJFF funded a Phase II trial by Oregon Health & Sciences University. (Donepezil is also in testing for Parkinson’s cognition.)

Medication targets the brain chemical acetylcholine, which may be related to imbalance and falls. MJFF is funding a Phase II trial at University of Michigan.

Drug is used to treat some forms of anxiety. MJFF is funding a Phase II trial at the University of Rochester.

Nutritional supplement may improve gut bacteria and ease constipation. MJFF is funding a Phase II trial at Saarland University.

Novel drug that works on the serotonin chemical system may speed stomach emptying and lessen constipation. MJFF is funding a Phase I trial at Virginia Commonwealth University.